U.S. Markets closed
  • S&P 500

    3,941.26
    -57.58 (-1.44%)
     
  • Dow 30

    33,596.34
    -350.76 (-1.03%)
     
  • Nasdaq

    11,014.89
    -225.05 (-2.00%)
     
  • Russell 2000

    1,812.58
    -27.65 (-1.50%)
     
  • Crude Oil

    74.45
    -2.48 (-3.22%)
     
  • Gold

    1,783.30
    +2.00 (+0.11%)
     
  • Silver

    22.35
    -0.07 (-0.30%)
     
  • EUR/USD

    1.0468
    -0.0030 (-0.2826%)
     
  • 10-Yr Bond

    3.5130
    -0.0860 (-2.39%)
     
  • Vix

    22.17
    +1.42 (+6.84%)
     
  • GBP/USD

    1.2133
    -0.0061 (-0.4999%)
     
  • USD/JPY

    136.9750
    +0.2900 (+0.2122%)
     
  • BTC-USD

    16,992.74
    +26.10 (+0.15%)
     
  • CMC Crypto 200

    400.49
    -1.32 (-0.33%)
     
  • FTSE 100

    7,521.39
    -46.15 (-0.61%)
     
  • Nikkei 225

    27,885.87
    +65.47 (+0.24%)
     

FDA Clears Organogenesis' Next Generation PuraPly Surgical Solution

  • Organogenesis Holdings Inc (NASDAQ: ORGO) has received the FDA 510k Clearance for PuraPly MZ, a brand extension to the PuraPly product portfolio.

  • Of the U.S.'s 40 to 50 million surgeries each year, up to 28% of surgical sites must be left open to heal.

  • Related: Organogenesis' Q2 Operating Income Fell 50%, Lowers Annual Guidance.

  • Organogenesis developed PuraPly MZ, a powder designed to support wound healing in deep, tunneling, and complex wounds to support clinicians and patients with these complex post-surgical wounds.

  • PuraPly MZ consists of native structured collagen designed to allow for maximum coverage and maintenance of optimal contact with the contours of the wound surface to support healing.

  • Price Action: ORGO shares are up 2.44% at $4.83 during the market session on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.